Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium

On February 23, 2026 Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, reported that two abstracts have been accepted for presentation at the 2026 ASCO (Free ASCO Whitepaper) Genitourinary (GU) Cancers Symposium (ASCO GU). The meeting is being held February 26-28, 2026, in San Francisco, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster presentations are below:

Title: "ctDNA monitoring of FGFR3-altered metastatic urothelial cancer treated with dabogratinib (formerly TYRA-300) in the SURF301 trial"

Abstract Number: 809
Session: Poster Session B: Prostate Cancer and Urothelial Carcinoma
Date and Time: February 27, 2026, 11:30 AM–12:45 PM PST
Presenting Author: Andrew J. Murtha, BSc, University of British Columbia, Vancouver, BC, Canada
Title: "A phase 2 multicenter, open-label study evaluating the efficacy and safety of dabogratinib (formerly TYRA-300) in participants with FGFR3-altered low-grade, intermediate risk non-muscle invasive bladder cancer (SURF302)"

Abstract Number: TPS886
Session: Trials in Progress Poster Session B: Urothelial Carcinoma
Date and Time: February 27, 2026, 11:30 AM–12:45 PM PST
Presenting Author: Gautam Jayram, MD, Urology Associates, Nashville, TN
More information can be found at the ASCO (Free ASCO Whitepaper) GU website. The posters will be available on the IR page of TYRA’s website following presentation at ASCO (Free ASCO Whitepaper) GU: View Source

(Press release, Tyra Biosciences, FEB 23, 2026, View Source [SID1234662873])